摘要
目的总结患者源性类器官(patient-derived organoid,PDO)模型和人源肿瘤异种移植(patientderived tumor xenograft,PDX)模型的研究现状、最新进展及其优缺点,深入分析二者在胰腺癌中的应用进展,以期为胰腺癌的临床前研究的模型选择提供新思路。方法对近年来国内外关于胰腺癌PDO和PDX模型研究的相关文献进行综述,并结合研究团队在这两种模型中的探索和应用进行深入探讨。结果PDO和PDX模型在肿瘤的临床前研究中应用范围较广,尤其在目前临床治疗效果较差的胰腺癌患者的基础研究方面发挥了巨大的作用,如胰腺癌的发病机制研究、新靶点和新药物的开发、临床前药物毒性和有效性检测等。结论PDO和PDX模型作为最有前景的肿瘤临床前研究模型,在胰腺癌研究中具有较好的应用价值。
Objective To understand the development,research status,advantages and disadvantages of patientderived organoid(PDO)and patient-derived tumor xenograft(PDX),and to summarize their applications in pancreatic cancer,so as to provide new ideas for the selection of early modeling of pancreatic cancer.Method The recent studies on PDO and PDX of pancreatic cancer at home and abroad were reviewed.ResultsThe PDO and PDX models had a wide range of applications in preclinical research of tumor,especially played an important role in the basic research of present pancreatic cancer patients with poor clinical treatment effects,such as the pathogenesis research of pancreatic cancer,developing new targets and new drugs,testing preclinical drug toxicity and effectiveness.Conclusion PDO and PDX,as classical tumor research model,have broad clinical application prospects in the research of pancreatic cancer.
作者
韦文
张岩
肖丽霞
王涛
周辉年
WEI Wen;ZHANG Yan;XIAO Lixia;WANG Tao;ZHOU Huinian(The Second Clinical School of Lanzhou University,Lanzhou 730000,P.R.China;Department of General Surgery,Lanzhou University Second Hospital,Lanzhou 730000,P.R.China)
出处
《中国普外基础与临床杂志》
CAS
2023年第6期739-744,共6页
Chinese Journal of Bases and Clinics In General Surgery
基金
甘肃省科技计划项目(自然科学基金)(项目编号21JR1RA144)
2022兰州大学第二医院萃英学子科研培育计划项目(项目编号:CYXZ2022-02)。
关键词
胰腺癌
患者源性类器官
人源肿瘤异种移植
pancreatic cancer
patient-derived organoid
patient-derived tumor xenograft
